Beijing Double-Crane Runchuang Technology Co. Ltd. has identified heterocyclic compounds reported to be useful for the treatment of cancer.

Sunrise Oncology (Hong Kong) Ltd. has synthesized molecular glues acting as GTPase KRAS (and/or its mutant)/RAF proto-oncogene serine/RAF1 interaction inhibitors reported to be useful for the treatment of cancer.

Guangzhou Diqi Pharmaceuticals Co. Ltd. has disclosed crystalline forms of rasagiline reported to be useful for the treatment of Parkinson’s disease.

Allorion Therapeutics Inc. has patented phosphoramidate macrocycle compounds acting as aldo-keto reductase family 1 member C3 (AKR1C3; 17β-HSD5) inhibitors potentially useful for the treatment of cancer.

Cancer Research Technology Ltd. and My-T Bio Ltd. have discovered Myt1 kinase (PKMYT1) inhibitors potentially useful for the treatment of cancer.

University of Eastern Finland has synthesized carbonic anhydrase II (CA2) inhibitors and melanin ligands. As such, they are described as potentially useful for the treatment of glaucoma, macular edema and retinal degeneration.

SK Biopharmaceuticals Co. Ltd. has identified sodium channel protein type 9 subunit α (SCN9A; Nav1.7) blockers reported to be useful for the treatment of neuropathic pain.

Novartis AG has reported macrocyclic compounds acting as pan-RAS inhibitors and therefore potentially useful for the treatment of cancer.

Researchers at Guangzhou Laboratory and Guangzhou Medical University have described compounds reported to be useful for the treatment of asthma, bronchitis, chronic obstructive pulmonary disease (COPD) and infectious pneumonia.

Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd. has divulged antibody-drug conjugates (ADCs) potentially useful for the treatment of cancer. The ADCs comprise an antibody or antigen-binding fragment linked to a cytotoxic drug through a linker.